SGMT Relative Valuation
SGMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SGMT is overvalued; if below, it's undervalued.
Historical Valuation
Sagimet Biosciences Inc (SGMT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.62. The fair price of Sagimet Biosciences Inc (SGMT) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：6.35
Fair
-3.56
PE
1Y
3Y
5Y
Trailing
Forward
-1.03
EV/EBITDA
Sagimet Biosciences Inc. (SGMT) has a current EV/EBITDA of -1.03. The 5-year average EV/EBITDA is -0.19. The thresholds are as follows: Strongly Undervalued below -1.57, Undervalued between -1.57 and -0.88, Fairly Valued between 0.50 and -0.88, Overvalued between 0.50 and 1.19, and Strongly Overvalued above 1.19. The current Forward EV/EBITDA of -1.03 falls within the Undervalued range.
-1.27
EV/EBIT
Sagimet Biosciences Inc. (SGMT) has a current EV/EBIT of -1.27. The 5-year average EV/EBIT is -1.52. The thresholds are as follows: Strongly Undervalued below -7.46, Undervalued between -7.46 and -4.49, Fairly Valued between 1.45 and -4.49, Overvalued between 1.45 and 4.43, and Strongly Overvalued above 4.43. The current Forward EV/EBIT of -1.27 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Sagimet Biosciences Inc. (SGMT) has a current PS of 0.00. The 5-year average PS is 6.61. The thresholds are as follows: Strongly Undervalued below -59.01, Undervalued between -59.01 and -26.20, Fairly Valued between 39.41 and -26.20, Overvalued between 39.41 and 72.22, and Strongly Overvalued above 72.22. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-4.17
P/OCF
Sagimet Biosciences Inc. (SGMT) has a current P/OCF of -4.17. The 5-year average P/OCF is -2.25. The thresholds are as follows: Strongly Undervalued below -8.45, Undervalued between -8.45 and -5.35, Fairly Valued between 0.84 and -5.35, Overvalued between 0.84 and 3.94, and Strongly Overvalued above 3.94. The current Forward P/OCF of -4.17 falls within the Historic Trend Line -Fairly Valued range.
-1.99
P/FCF
Sagimet Biosciences Inc. (SGMT) has a current P/FCF of -1.99. The 5-year average P/FCF is -0.93. The thresholds are as follows: Strongly Undervalued below -3.56, Undervalued between -3.56 and -2.24, Fairly Valued between 0.38 and -2.24, Overvalued between 0.38 and 1.69, and Strongly Overvalued above 1.69. The current Forward P/FCF of -1.99 falls within the Historic Trend Line -Fairly Valued range.
Sagimet Biosciences Inc (SGMT) has a current Price-to-Book (P/B) ratio of 1.73. Compared to its 3-year average P/B ratio of 1.08 , the current P/B ratio is approximately 60.87% higher. Relative to its 5-year average P/B ratio of 1.08, the current P/B ratio is about 60.87% higher. Sagimet Biosciences Inc (SGMT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -21.99%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -21.99% , the current FCF yield is about -100.00% lower.
1.73
P/B
Median3y
1.08
Median5y
1.08
-21.34
FCF Yield
Median3y
-21.99
Median5y
-21.99
Competitors Valuation Multiple
The average P/S ratio for SGMT's competitors is 0.00, providing a benchmark for relative valuation. Sagimet Biosciences Inc Corp (SGMT) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SGMT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SGMT in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Sagimet Biosciences Inc (SGMT) currently overvalued or undervalued?
What is Sagimet Biosciences Inc (SGMT) fair value?
How does SGMT's valuation metrics compare to the industry average?
What is the current P/B ratio for Sagimet Biosciences Inc (SGMT) as of Dec 05 2025?
What is the current FCF Yield for Sagimet Biosciences Inc (SGMT) as of Dec 05 2025?
What is the current Forward P/E ratio for Sagimet Biosciences Inc (SGMT) as of Dec 05 2025?